Vopratelimab  (Synonyms: JTX 2011)

Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response^[1].

Vopratelimab (JTX-2011; 0.001-10 μg/mL; 3 d; CD4 T cells) has the activity of activating primary human T cells, driving IFNγ, IL-17a, IL-10, IL-9, GM-CSF, TNFα, and IL-21 secretion^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; twice a week, for 2 weeks) promotes tumor regression in the Sa1/N murine syngeneic tumor model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2039148-04-2

Liquid

Colorless to light yellow

[Vopratelimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595.  [Content Brief]